Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Interest & Investment Income for 10 consecutive years, with $6.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 39.08% to $6.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $29.2 million, a 38.93% decrease, with the full-year FY2025 number at $29.2 million, down 38.93% from a year prior.
  • Interest & Investment Income was $6.5 million for Q4 2025 at Intellia Therapeutics, down from $6.7 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $12.7 million in Q3 2023 to a low of $211000.0 in Q2 2021.
  • A 5-year average of $6.8 million and a median of $7.1 million in 2025 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: crashed 82.29% in 2021, then skyrocketed 2118.52% in 2023.
  • Intellia Therapeutics' Interest & Investment Income stood at $503000.0 in 2021, then skyrocketed by 964.41% to $5.4 million in 2022, then soared by 132.7% to $12.5 million in 2023, then fell by 14.67% to $10.6 million in 2024, then tumbled by 39.08% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Interest & Investment Income are $6.5 million (Q4 2025), $6.7 million (Q3 2025), and $7.4 million (Q2 2025).